Spots Global Cancer Trial Database for Pembrolizumab in Combination With Doxorubicin in Advanced, Recurrent or Metastatic Endometrial Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Pembrolizumab in Combination With Doxorubicin in Advanced, Recurrent or Metastatic Endometrial Cancer
Official Title: Phase II Trial of Pembrolizumab in Combination With Doxorubicin in Advanced, Recurrent or Metastatic Endometrial Cancer (TOPIC)
Study ID: NCT03276013
Conditions
Interventions
Study Description
Brief Summary: This is a non-randomized, single arm, multi-center, phase II study of pembrolizumab in combination with doxorubicin in subjects with recurrent/metastatic endometrial cancer.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Institut Català d'Oncologia L'Hospitalet (ICO L'Hospitalet), Hospitalet de Llobregat, Barcelona, Spain
Hospital Vall d'Hebron, Barcelona, , Spain
Hospital Universitario Reina Sofía- Córdoba, Córdoba, , Spain
CUN - Madrid, Madrid, , Spain
El Centro Integral Oncológico Clara Campal (HM CIOCC),, Madrid, , Spain
Hospital Universitario La Paz Madrid, Madrid, , Spain
Hospital Clínico Universitario Lozano Blesa, Zaragoza, , Spain
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
